Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac ® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study.

Phoom NarongkiatikhunKajohnsak NoppakunRomanee ChaiwarithPoramed WinichakoonSurachet VongsanimYuttitham SuteekaKarn PongsuwanPrit KusirisinNuttanun WongsarikanKanda FanhchaksaiChantana KhamwanDararat DankaiVuddhidej Ophascharoensuk

Published in: Vaccines (2023)

Immunization with SV-SV, AZ-AZ, and SV-AZ could generate humoral immunity without any serious adverse events among MHD patients. Using the heterologous vaccine prime-boost seemed to be more efficacious in terms of inducing immunogenicity.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
immune response
chronic kidney disease
prognostic factors
saccharomyces cerevisiae
peritoneal dialysis
cross sectional
patient reported
patient reported outcomes